Kornimate/medical-research-clean huggingface dataset:
the effects of auditory cueing on rhythmic movement and cortical excitability in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is a progressive degenerative disease of central nervous systems deficit. the clinical symptoms of parkinson's disease include the following motor tasks: difficult in initiating movement, performing rhythmic movement or serial movement, the ability of learning motor movement is also affected. the primary treatment for parkinson's disease is medical treatment; surgery is used if in need. rehabilitation such as physical therapy, which aims to improve patient's quality of life and functions, is a non-invasive treatment and value for pd patients. auditory cue is a technique that widely applied on training patients with parkinson's disease, and some researches revealed that auditory cueing could improve motor performance. however, the mechanism under this treatment technique is still unknown. this study is to investigate the effect of auditory cueing on rhythmic finger movement in patients with parkinson's disease. to investigate the mechanism under auditory cueing, neurophysiological data such as motor cortex excitability and blood flow in cortical cortex will be obtained by using transcranial magnetic stimulation (tms) and near infrared spectroscopy (nirs).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson disease exclusion criteria: * clinical diagnosis of other neurological diseases * dementia * been diagnosed with any mental illness * history of seizures * brain trauma * body with a pacemaker or other electrical stimulator * pregnancy

Keywords: parkinson's disease auditory cueing
auricular acupuncture vs. progressive muscle relaxation in patients with anxiety disorders or major depressive disorder.

Conditions: Anxiety Disorders; Depressive Disorder, Major

Summary: the purpose of this study is to determine whether auricular acupuncture (aa) according to the nada protocol and progressive muscle relaxation (pmr) differ in their effectiveness of treating people with anxiety disorders or major depressive disorder. we hypothesized, that both treatments show significant effects in alleviating the examined items (tension, anxiety, anger/aggression and state ofr mood) and that there is no significant difference between these two treatments.

the purpose of this study is to determine whether auricular acupuncture according to the nada protocol and progressive muscle relaxation differ in their effectiveness of treating people with anxiety disorders (ad) or major depressive disorder (mdd). in this study, acupuncture was executed according to the nada protocol: a standardized and comparable method of auricular acupuncture (aa) with ease of application and limited adverse reactions, which seems to have high acceptance among psychiatric patients. the nada (national acupuncture detoxification association) protocol includes the needling of five specific acupuncture points on both ears. as a comparative relaxation treatment, progressive muscle relaxation (pmr) was applied in our study. it has been well established for many decades, especially for the treatment of severe states of physical and mental tension, which is a common symptom of anxiety disorders and depression. many studies also suggest its potential utility in the treatment program of many other illnesses, which are associated with conditions of anxiety and depression, such as schizophrenia, sleeping disorders, endometriosis, atopic dermatitis or cancer. the main aim of this study was to examine the effectiveness of aa according to the nada protocol versus pmr in patients with ad or mdd. we hypothesized, that both treatments show significant effects in alleviating the examined items (tension, anxiety, anger/aggression and state ofr mood) and that there is no significant difference between these two treatments. in order to increase the patients´ treatment acceptance and compliance, this study was set up in an open design in which each patient was freely able to choose between both treatments.

Eligibility criteria:
inclusion criteria: * patient at our psychiatric ward or day-hospital * meeting the dsm-iv diagnostic criteria for the primary diagnosis of an anxiety disorder oder major depressive disorder exclusion criteria: * ear infection * anamnestic substance abuse or positive drug screening * taking opioid analgesics * suffering from schizophrenic or organic cerebral psychosis

Keywords: acupuncture auricular acupuncture nada anxiety depression
umbilical cord-derived mesenchymal stem cells for ischemic stroke

Conditions: Ischemic Stroke

Summary: this is a doble blind, placebo controlled clinical trial to assess safety and efficacy of intravenous administration of umbilical cord-derived mesenchymal stem cells in patients with ischemic stroke within 6 months of onset.


Eligibility criteria:
inclusion criteria: 1. age: 18-80 years old; 2. patients with anterior circulation cerebral infarction; 3. nihss: 6-25, and the limb movement score is at least 2 points; 4. hemoglobin \> 115g / l, platelet \> 100 × 109 / l, leukocyte \> 3 × 109 / l; 5. the time from onset to treatment: group a（6-24 hours）、group b（1-3 days）、gourp c（4-7 days）、group d（1-4 weeks）、group e（1-6 months）; 6. the patient or the legal representative of the patient can and is willing to sign the informed consent. exclusion criteria: 1. patients who need or expect decompressive craniectomy; 2. patients who need or are expected to receive endovascular treatment ; 3. patients receiving intravenous thrombolysis; 4. disturbance of consciousness； 5. pregnant women or women of childbearing age who have not taken effective contraceptive measures; 6. intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc; 7. posterior circulation cerebral infarction; 8. tumor patients; 9. epilepsy patients; 10. severe neurological deficit caused by stroke (mrs = 5); 11. previous diseases with obvious functional impairment, such as parkinson's disease, motor neuron disease, moderate alzheimer's disease, osteoarthritis, etc; 12. patients with history of coagulation disorders, systemic bleeding tendency and thrombocytopenia (\< 100000 / mm3); 13. chronic liver disease, liver and kidney dysfunction, elevated alt or ast (2 times higher than the upper limit of normal value), elevated serum creatinine (1.5 times higher than the upper limit of normal value) or dependent on renal dialysis; 14. patients with moderate to severe mental illness obviously interfere with treatment compliance; 15. patients with high blood pressure (systolic blood pressure \> 180mmhg) or low blood pressure (systolic blood pressure \< 90mmhg); 16. the expected survival time is less than one year; 17. those who have conducted other trials within 3 months; 18. other circumstances considered unsuitable by the researcher.

Keywords: ischemic stroke stem cell
safety and efficacy study of pn2034 in type 2 diabetes patients on concomitant rosiglitazone and metformin (or avandamet)

Conditions: Type 2 Diabetes Mellitus

Summary: this study is designed to evaluate the safety and efficacy of pn2034 administered to type 2 diabetics on concomitant rosiglitazone and metformin (or avandamet) therapy as measured by change in glycosylated hemoglobin (hba1c) levels from baseline to week 12. also the study will evaluate the effect of pn2034 on glucose control as measured by fasting plasma glucose (fpg) and on fasting lipid levels: triglycerides, total cholesterol, high-density lipoproteins (hdl), low-density lipoproteins (ldl), and very low-density lipoproteins (vldl).


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes mellitus * 21 to 72 years of age * taking rosiglitazone and metformin (or avandamet) for at least 3 months, and on a stable dose of rosiglitazone (or avandamet) for at least 2 months * glycosylated hemoglobin (hba1c) level of \>/=7.5% but \</=10.0% * fasting blood sugar level \>/= 125 mg/dl but \</= 279 mg/dl * bmi 26-43 kg/m2 * direct bilirubin \< 1.5x the upper limit of normal (uln) * serum creatinine \< 1.5 mg/dl (males) or \< 1.4 mg/dl (females) * blood urea nitrogen (bun)\</=40 mg/dl * all other clinical laboratory parameters (hematology, serum chemistry, and urinalysis) within normal limits or not clinically significant * ecg normal, or abnormalities not clinically significant * surgically sterile, postmenopausal, or using adequate contraception and have a negative pregnancy test at screening * willing and able to sign an informed consent form exclusion criteria: * diagnosed with type 1 diabetes mellitus or has a history of ketoacidosis * treatment with insulin, tzds (excluding rosiglitazone) or any other oral or injected antidiabetic (excluding metformin or avandamet) within 3 months prior to screening or during study treatment * change in lipid-lowering medication within 2 months of screening * taken systemic corticosteroids within 1 month prior to screening or during study treatment * history of or current/active cardiovascular disease * significant current pulmonary conditions * significant thyroid disease * cpk value \> 3x uln * a female who is pregnant or lactating * systolic bp \> 160 mm hg or a diastolic bp \> 90 mm hg at screening * previous or current history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission within 5 years prior to randomization * liver function tests (alt, ast, alp) \> 2 times uln, or active liver disease at screening * history of positive hiv * positive hepatitis b test at screening * weight loss or gain \>/= 15 lbs within 3 months of screening * history of substance abuse (including alcohol abuse) within 2 years prior to screening * donated and/or received any blood or blood products within 3 months prior to randomization * taken an investigational study medication within 30 days prior to screening or during the study

Keywords: diabetes, type 2
parameters of neurological deficit after thoracolumbar fractures

Conditions: SPINAL Fracture

Summary: to detect radiological parameters affecting neurological injury after thoracolumbar spinal fractures.

thoracolumbar spine fractures are the most common spinal column fractures. high activity and lack of stability make it more prone to fractures. many studies have attempted to determine whether the neurological deficit in such fractures is related to spinal canal stenosis or other parameters observed on axial computed tomography (ct). however, this relationship remains controversial. few reports shed light on the relation between different imaging parameters like sagittal alignment, vertebral body compression, canal stenosis, and type of fracture according to ao classification with the severity of nerve damage. these four radiographic parameters will be tested as expected risk factors for the neurological deficit in thoracolumbar fractures.

Eligibility criteria:
inclusion criteria: 1. any patient with acute (within one month) thoracolumbar spine fracture above 18 years old with or without neurological deficit 2. in orthopaedics and trauma department of assiut university hospital from 1st of november 2018 to 31 st of october 2019. exclusion criteria: * patients younger than 18 years old. * patients suffering from preoperative neurological diseases that hinder our examination like peripheral neuropathy or previous strokes. * obtuned patients who cannot be properly examined like those with low gcs score. * patients with old thoracolumbar fractures more than one month duration. * patients with pathological spine fractures like those with osteoporosis and cancer metastasis. * patients with fracture type a0 according to ao classification.

Keywords: neurological deficit
double blind randomized trial to compare gurmar (gymnema sylvestre) with metformin in type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the study plans to compare the glucose-lowering effect of gurmar, a herbal preparation, with metformin in patients with type 2 diabetes


Eligibility criteria:
inclusion criteria: * newly detected type 2 diabetes * fasting plasma glucose \>126mg/dl * hba1c \> 7% exclusion criteria: * serious comorbid illnesss * history of drug abuse * history of recent weight loss
glutaminergic transmission in autism : molecular imaging exploration

Conditions: Autism; Fragile-X Syndrome (FXS); Healthy Volunteers

Summary: glutamatergic transmission exploration using pet (positron emission tomography) imaging in autism compared to fragile-x syndrome ( fxs) and healthy volunteers


Eligibility criteria:
inclusion criteria: * male * between 18 years-old and 45 years-old * informed, written consent obtained from patient or his representant * subject with an affiliation to french social security * for autistic patient : patient with diagnosis of asd (autistic spectrum disorders) following dsm-iv or dsm-5 criteria with recommended tools (adi-r and/or ados) * for fxs patient : diagnosis of fxs and confirmation of total mutation of fmr1 exclusion criteria: * contraindications to mri * excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months * any unstable or uncontrolled disease, clinically significant * participation to an other experimental protocol with drug or irradiant exam * person under exclusion period because of previous participation to an other experimental protocol * person under temporary guardianship * forbidden treatments : any psychotropic treatment for 4 last weeks before pet exam and changing durably glutaminergic transmission directly or undirectly * for healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (mini dsm-iv)

Keywords: autism fragile x syndrome (fxs) pet (positron emission tomography) glutamate
emergency room evaluation and recommendations for older users of emergency departments

Conditions: Elderly Care; Length of Hospital Stay; Multimorbidity

Summary: the study evaluates if the emergency room evaluation and recommendation tool (er2) reduces the hospital admission rate and the length of stay in emergency.

regardless of the reason for ed visit and its care plan, there are simple interventions, which may be continued to prevent short-term ed adverse outcomes. delirium, motor deconditioning, adverse drug reactions due to polypharmacy, and inappropriate home support are the main conditions to target when taking care of older er users. evidence based medicine showed that simple and early intervention in the process of care may prevent delirium (e.g., hydration, avoid restraint, mobilize and satisfy basic needs, time and place reorientation) and motor deconditioning (e.g., encourage mobility, up to chair at meal time during day light hours, provide appropriate walking aid) in older patients. the medication reconciliation is also an efficient intervention for the prevention of adverse drug reactions. furthermore, an early assessment of home support is a crucial step to adjust home services for an early discharge to home.

Eligibility criteria:
inclusion criteria: * being 75 years old and over * being brought at emergency on medical stretcher exclusion criteria: * being less than 75 years old * never come at emergency
rehabilitation for patients with persistent symptoms post covid-19

Conditions: Covid19

Summary: a large proportion of persons who have had covid-19 have reported persisted symptoms as fatigue and dyspnea months post infection which affect activities of daily living. the aim of the study is to examine the feasibility and safety of a concentrated rehabilitation program with a mobile application follow-up for persons with persistent symptoms post covid-19 infection. we will examine recruitment availability, adherence to the program, goal achievement, and resources requirements. methods: a feasibility study with one group pre-post test design with 10-20 persons between 18-67 years, with persistent symptoms post covid-19 will be included. the intervention is 3+ 1-2 days concentrated rehabilitation with a mobile application follow-up for 3 months. following assessments wil be used: cardiopulmonary exercise testing, lung function, functional performance tests, questionnaires regarding dyspnea, fatigue, anxiety, depression, work-status, health status, sleep behavior, physical activity level. demographic data before and after the intervention will be presented. focus group interview will be done with the participants. the interview will be analysed using systematic text condensation.

in march 2020, the world health organization (who) declared the covid-19 outbreak to be a pandemic, and a year later more than 120 000 000 people are confirmed with the disease. the disease has caused more than 2 700 000 deaths globally. norway has a low mortality rate compared to rest of the world. however, a large proportion (10-33%) of the patients worldwide have reported persistent symptoms, such as dyspnea, reduced exercise capacity, loss of taste/smell and fatigue months after the infection. persistent symptoms are also found in younger populations and in persons with an initially mild disease. the intervention will take place at "helse i hardanger" (hih)(health center in hardanger, norway). the participants will stay for a 3 -day rehabilitation intervention, if needed, another 1 or 2-day stay will be offered about a month later. the concentrated treatment will be given by an interdisciplinary team, including doctors, physiotherapists, nutritionists, pharmacists, psychologists/psychiatrists, and nurses. the intervention is an individualized group treatment based on behavioural change.

Eligibility criteria:
inclusion criteria: * persistent symptoms minimum 2 months post covid-19 infection * reduced exercise capacity level * symptoms of dyspnea and/or fatigue exclusion criteria: * diseases where exercise is contraindicated (e.g. unstable angina pectoris) * drug abuse, severe mental illness where treatment in groups are contraindicated.

Keywords: long covid post-acute covid syndrome persistent symptoms post covid-19
preventing medication-related problems in care transitions to skilled nursing facilities

Conditions: Care Transition

Summary: the pharmacy integrated transitions (pit) program, utilizes a crossover randomized control design to evaluate the impact of a clinical pharmacist in decreasing medication related problems during a patient's transition from hospital to skilled nursing facility (snf).

standard hospital discharge processes (e.g. as recommended by the joint commission center for transforming healthcare), include hospital staff completing a paper-based discharge summary and medication reconciliation form. to reduce the likelihood of medication-related problems during care transitions, the pharmacy integrated transitions (pit) program aims to improve the standard transition process by adding a coordinating transitional pharmacist to provide a structured synchronous "warm-handoff" between clinical teams at the hospital and the skilled nursing facility, in addition to reconciling, adjusting, and monitoring medications during and after discharge from the hospital.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * patients receiving inpatient care at university of washington mountlake, university of washington northwest, harborview, and valley medical center hospitals to one of 14 collaborating snf's on a day when the pit program pharmacist is conducting the intervention exclusion criteria: * under 18 years of age * patients with a discharge on hospice care * patients discharged on days that the pharmacist is not conducting the intervention

Keywords: care transition medication-related problems post-acute care skilled nursing facility hospital systems medication safety
glaukos® istent infinite trabecular micro-bypass system in subjects with mild to moderate primary open-angle glaucoma

Conditions: Glaucoma

Summary: prospective, multicenter, single-arm study of the istent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment


Eligibility criteria:
inclusion criteria: * diagnosis of primary open-angle glaucoma * phakic or pseudophakic * age 35 years or older exclusion criteria: * traumatic, uveitic, neovascular, angle-closure glaucoma or * glaucoma associated with vascular disorders * active corneal inflammation or edema * retinal disorders not associated with glaucoma
individual versus grouped debriefing approaches in anaesthesia crisis simulation-based training. what impact on the technical score ?

Conditions: Cardiac Arrest; Pregnancy

Summary: simulation-based training is essential in learning or maintaining skills in high risk industry such as aviation and railway and in the medical field like anaesthesia. debriefing following simulation is fundamental in order to reduce the emotional impact of the session and to asses the technical and non-technical skills (behavior). even if the ideal debriefing method is still to be found, individual debriefing is considered as the gold standard but time consuming. the debrief-sim study is a prospective, single blinded, multicentric and randomized study that will compare the individual (defined by learning couple resident and nurse) approach to a grouped (several couples) debriefing. the primary end point is to define the noninferiority of this approach compared to the individual one on the educational impact. the learners will be debriefed according to their randomization after the first session, but will all undergo individual debriefing following the second session.

individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated. grouped debriefing consists in the analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the grouped debriefing group.

Eligibility criteria:
inclusion criteria: * doctor: * resident in anesthesia and intensive care chu besançon and dijon student nurse anesthetist: * student nurse anesthesist 1st or 2nd year of school besançon and dijon exclusion criteria: * subjects incapable of giving consent: incapacitated (subjects under guardianship), minors (\< 18 years) * refusal to participate in the study * refusal to sign the confidentiality clause

Keywords: simulation debriefing anaesthesia crisis management cardiac arrest pregnancy
the effect of lifestyle-adjustments prior to medical treatment on the effect of medical treatment in reflux patients

Conditions: GERD; Quality of Life

Summary: the purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)


Eligibility criteria:
inclusion criteria: * patients with reflux complaints * 18 years of age exclusion criteria: * restrictions as mentioned in the registration text * h2ra or ppi use in the month prior to inclusion

Keywords: patients with reflux complaints gerd quality of life lifestyle adjustments